Central Pharmaceutical JSC No. 3 Adjusts Valuation Amid Mixed Financial Indicators and Market Sentiment
Central Pharmaceutical JSC No. 3 has experienced a recent evaluation adjustment, reflecting significant changes in its financial metrics. The company now holds a fair valuation grade, supported by a competitive P/E ratio, strong returns on capital and equity, and a favorable enterprise value to EBITDA ratio, despite a bearish technical trend.
Central Pharmaceutical JSC No. 3 has recently undergone an adjustment in evaluation, reflecting notable shifts in its financial metrics. The company's valuation grade has transitioned to a fair assessment, indicating a more favorable position compared to previous evaluations. Key metrics contributing to this adjustment include a price-to-earnings (P/E) ratio of 9, which positions the stock competitively within its industry. Additionally, the company showcases a robust return on capital employed (ROCE) of 113.83% and a return on equity (ROE) of 24.96%, highlighting its efficiency in generating profits relative to its equity base. The enterprise value to EBITDA ratio stands at 5.12, further supporting the revised valuation.
On the technical side, the stock's technical trend has shifted, reflecting a bearish sentiment in the market. Various indicators, including the moving averages and Bollinger Bands, suggest a cautious outlook in the short term.
Overall, the adjustments in Central Pharmaceutical JSC No. 3's evaluation underscore a complex interplay of valuation and technical factors that investors may find noteworthy.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
